Total number of shares and voting rights in Zealand Pharma at June 30, 2022
Zealand Pharma A/S (NASDAQ: ZEAL) announced its total number of shares and voting rights as of June 30, 2022, following changes to its share capital. The company reported a total of 46,526,510 shares and voting rights, reflecting its capital structure post-private placement. Zealand, a biotechnology firm specializing in peptide-based medicines, has advanced multiple drug candidates into clinical development. The announcement complies with the Danish Capital Markets Act and aims to inform shareholders about the company's updated share metrics.
- Total shares and voting rights reported at 46,526,510.
- Company focuses on peptide-based medicines with several candidates in clinical stages.
- None.
Company announcement – No. 30 / 2022
Total number of shares and voting rights in Zealand Pharma at June 30, 2022
Copenhagen, DK and Boston, MA, June 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
In Company announcement No. 26/2022 from June 3, 2022, Zealand announced an increase in share capital relating to a private placement. Following this announcement, the table below lists the total number of shares and voting rights in Zealand up to and including June 30, 2022.
Date | Number of shares (nominal value of DKK 1 each) | Share capital (nominal value in DKK) | Number of voting rights |
| June 30, 2022 | 46,526,510 | 46,526,510 | 46,526,510 |
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 and headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.
For further information, please contact:
| Zealand Pharma Investor Relations |
| Maeve Conneighton |
| Argot Partners |
| investors@zealandpharma.com |
| Zealand Pharma Media Relations |
| David Rosen |
| Argot Partners |
| media@zealandpharma.com |
FAQ
What is the total number of shares for Zealand Pharma as of June 30, 2022?
How many voting rights does Zealand Pharma have at the end of June 2022?
What does Zealand Pharma focus on as a biotechnology company?
